<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01602679</url>
  </required_header>
  <id_info>
    <org_study_id>16085</org_study_id>
    <secondary_id>R01HD058671</secondary_id>
    <nct_id>NCT01602679</nct_id>
  </id_info>
  <brief_title>Acute Effects of Progesterone on LH Pulses During the Follicular Phase (CRM006)</brief_title>
  <official_title>Acute Effects of Progesterone on LH Pulses During the Follicular Phase</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Virginia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Virginia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The rapidity with which progesterone slows LH (and by inference GnRH) pulse frequency in
      women is unclear. The investigators hypothesize that progesterone slows LH pulse frequency
      within 10 hours. The investigators propose to assess this further with a randomized,
      cross-over, placebo-controlled study. Regularly cycling women without hyperandrogenism will
      be admitted to the Clinical Research Unit on cycle day 5-9 (mid-follicular phase) for a 10
      hour frequent sampling study to observe LH, FSH, estradiol, progesterone, and testosterone.
      Either oral micronized progesterone suspension or placebo will be administered at 0900 h.
      During a subsequent menstrual cycle, subjects will undergo another study identical to the
      first except that oral progesterone will be exchanged for placebo or vice versa in accordance
      with a crossover design.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The rapidity with which progesterone slows LH (and by inference GnRH) pulse frequency in
      women is unclear. The investigators hypothesize that progesterone slows LH pulse frequency
      within 10 hours. The investigators propose to assess this further with a randomized,
      cross-over, placebo-controlled study. Regularly cycling women without hyperandrogenism will
      be admitted to the Clinical Research Unit on cycle day 5-9 (mid-follicular phase) for a
      frequent sampling study. Beginning at 0900 h, blood for LH, FSH, estradiol, progesterone, and
      testosterone will be obtained over a 10-hour period. Either oral micronized progesterone (100
      mg p.o.) suspension or placebo will be administered at 0900 h. During a subsequent menstrual
      cycle, subjects will undergo another study identical to the first except that oral
      progesterone will be exchanged for placebo or vice versa in accordance with a crossover
      design. The primary endpoint of interest is LH pulse frequency; the investigators will
      compare LH pulse frequency after progesterone administration to LH pulse frequency after
      placebo administration.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Interim analysis suggested futility.
  </why_stopped>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">July 31, 2015</completion_date>
  <primary_completion_date type="Actual">July 31, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized, placebo-controlled, crossover study</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Number of LH Pulses Per Hour</measure>
    <time_frame>10 hours following administration of micronized progesterone or placebo</time_frame>
    <description>The primary endpoint is the change in the number of LH pulses per hour (over 10 h), comparing (a) number of LH pulses at baseline to (b) number of LH pulses immediately after progesterone or placebo administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Mean LH</measure>
    <time_frame>10 hours following administration of micronized progesterone or placebo</time_frame>
    <description>This secondary endpoint is the change of the mean LH (over 10 h), comparing (a) mean LH at baseline to (b) mean LH immediately after progesterone or placebo administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean LH Amplitude</measure>
    <time_frame>10 hours following administration of micronized progesterone or placebo</time_frame>
    <description>This secondary endpoint is the change in the mean LH amplitude (over 10 h), comparing (a) mean LH amplitude at baseline to (b) mean LH amplitude immediately after progesterone or placebo administration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Female Reproductive Physiology</condition>
  <arm_group>
    <arm_group_label>micronized progesterone, then placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants first received oral micronized progesterone (100 mg p.o.) suspension. After a washout period of approximately 20 days, they then received placebo (matching oral micronized progesterone suspension).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, then micronized progesterone</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants first received placebo. After a washout period of approximately 20 days, they then received oral micronized progesterone syrup (100 mg p.o.)Placebo contains only inert ingredients and is not expected to exert any direct physiological effects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oral micronized progesterone suspension</intervention_name>
    <description>oral micronized progesterone (100 mg p.o.) suspension</description>
    <arm_group_label>Placebo, then micronized progesterone</arm_group_label>
    <arm_group_label>micronized progesterone, then placebo</arm_group_label>
    <other_name>Progesterone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo contains only inert ingredients and is not expected to exert any direct physiological effects</description>
    <arm_group_label>Placebo, then micronized progesterone</arm_group_label>
    <arm_group_label>micronized progesterone, then placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects will be healthy women with regular menstrual cycles and no evidence of
             hyperandrogenism.

          -  Subjects will be 18-30 years old; the investigators use a cutoff age of 30 years
             because age-related alterations in the hypothalamic-pituitary-ovarian axis is uncommon
             before age 30 years.

          -  Subjects will be willing to strictly avoid pregnancy (using non-hormonal methods)
             during the time of study and must be willing and able to provide informed consent.

        Exclusion Criteria:

          -  Pregnancy

          -  Lactation

          -  History of allergy to progesterone

          -  BMI &lt; 18 kg/m2 or &gt; 30 kg/m2 (underweight and obesity can affect
             hypothalamic-pituitary-ovarian function)

          -  Excessive exercise, defined as routine and current engagement in either (a) moderate
             exercise (e.g., brisk walking) exceeding 14 hours per week or (a) vigorous exercise
             exceeding 7 hours a week.

          -  Clinical hyperandrogenism (primarily hirsutism)

          -  Abnormally elevated free testosterone or DHEAS concentration

          -  A previous diagnosis of diabetes, a fasting glucose â‰¥ 126 mg/dl

          -  Abnormal TSH (subjects with adequately treated hypothyroidism, reflected by normal TSH
             values, will not be excluded; or, for a new diagnosis of hypothyroidism, further study
             will at the least be delayed pending appropriate treatment) (confirmed on repeat)

          -  Abnormal prolactin (confirmed on repeat)

          -  Evidence of Cushing's syndrome by history or physical exam

          -  History of venous thromboembolism, breast/ovarian/endometrial cancer

          -  The investigators will exclude women with any other cancer diagnosis and/or treatment
             (with the exception of basal cell or squamous skin carcinoma) unless they have
             remained clinically disease free (based on appropriate surveillance) for five years.

          -  Women with anemia (hematocrit &lt; 36% and hemoglobin level &lt; 12 g/dl) will be treated
             with iron for a maximum of 2 sequential months before the 1st admission and/or before
             the 2nd admission. If they remain anemic after 2 sequential months of ferrous
             gluconate (325 mg bid), they will then be excluded from further participation in the
             study.

          -  Women with a significant history of cardiac or pulmonary dysfunction (e.g., known or
             suspected congestive heart failure; known or suspected coronary atherosclerosis;
             asthma requiring systemic intermittent corticosteroids; etc.) will be excluded.

          -  Women with liver enzymes, alkaline phosphatase, or bilirubin &gt; 1.5 times upper limit
             of normal (confirmed on repeat) will be excluded, with the exception that mild
             bilirubin elevations will be accepted in the setting of known Gilbert's syndrome.

          -  Abnormal sodium or potassium concentrations (confirmed on repeat); bicarbonate
             concentrations &lt;20 or &gt;30 (confirmed on repeat)

          -  Women with abnormal renal function (i.e., serum creatinine &gt; 1.4) will be excluded
             (confirmed on repeat)

          -  Due to the amount of blood being drawn in the study, subjects with body weight &lt; 110
             pounds will be excluded from the study

          -  Being a study of the acute effects of progesterone on the hypothalamic-pituitary unit,
             subjects must not take hormonal medications (e.g., oral contraceptives) or other
             medications known to affect the reproductive axis for 60 days prior to the study and
             during the study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher R. McCartney, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Virginia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Research in Reproduction</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>May 17, 2012</study_first_submitted>
  <study_first_submitted_qc>May 18, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2012</study_first_posted>
  <results_first_submitted>July 31, 2018</results_first_submitted>
  <results_first_submitted_qc>October 15, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 16, 2018</results_first_posted>
  <last_update_submitted>October 15, 2018</last_update_submitted>
  <last_update_submitted_qc>October 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 16, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Virginia</investigator_affiliation>
    <investigator_full_name>Chris McCartney</investigator_full_name>
    <investigator_title>Associate Professor of Medicine</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Progesterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>We do not have current plans to share IPD</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 24, 2014</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/79/NCT01602679/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>12 subjects enrolled in this study. 5 subjects completed screening procedures only (these 5 subjects were withdrawn from study prior to being assigned to an arm of intervention).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Oral Micronized Progesterone Suspension, Then Placebo</title>
          <description>Participants first received oral micronized progesterone (100 mg p.o.) suspension. After a washout period of approximately 20 days, they then received placebo.
oral micronized progesterone suspension: oral micronized progesterone (100 mg p.o.) suspension</description>
        </group>
        <group group_id="P2">
          <title>Placebo, Then Oral Micronized Progesterone Suspension</title>
          <description>Participants first received Placebo. After a washout period of approximately 20 days, they then received oral micronized progesterone suspension. Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
Placebo: Placebo contains only inert ingredients and is not expected to exert any direct physiological effects</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Oral Micronized Progesterone Suspension, Then Placebo</title>
          <description>Participants first received oral micronized progesterone (100 mg p.o.) suspension. After a washout period of approximately 20 days, they then received Placebo.
oral micronized progesterone suspension: oral micronized progesterone (100 mg p.o.) suspension Placebo: Placebo contains only inert ingredients and is not expected to exert any direct physiological effects</description>
        </group>
        <group group_id="B2">
          <title>Placebo, Then Oral Micronized Progesterone Suspension</title>
          <description>Participants first received Placebo. After a washout period of approximately 20 days, they then received oral micronized progesterone suspension. Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
Placebo: Placebo contains only inert ingredients and is not expected to exert any direct physiological effects oral micronized progesterone suspension: oral micronized progesterone (100 mg p.o.) suspension</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="7"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Number of LH Pulses Per Hour</title>
        <description>The primary endpoint is the change in the number of LH pulses per hour (over 10 h), comparing (a) number of LH pulses at baseline to (b) number of LH pulses immediately after progesterone or placebo administration</description>
        <time_frame>10 hours following administration of micronized progesterone or placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Micronized Progesterone Suspension</title>
            <description>oral micronized progesterone (100 mg p.o.) suspension
oral micronized progesterone suspension: oral micronized progesterone (100 mg p.o.) suspension</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
Placebo: Placebo contains only inert ingredients and is not expected to exert any direct physiological effects</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Number of LH Pulses Per Hour</title>
          <description>The primary endpoint is the change in the number of LH pulses per hour (over 10 h), comparing (a) number of LH pulses at baseline to (b) number of LH pulses immediately after progesterone or placebo administration</description>
          <units>pulses/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="0.28"/>
                    <measurement group_id="O2" value="0.79" spread="0.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean LH</title>
        <description>This secondary endpoint is the change of the mean LH (over 10 h), comparing (a) mean LH at baseline to (b) mean LH immediately after progesterone or placebo administration</description>
        <time_frame>10 hours following administration of micronized progesterone or placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Micronized Progesterone Suspension</title>
            <description>oral micronized progesterone (100 mg p.o.) suspension
oral micronized progesterone suspension: oral micronized progesterone (100 mg p.o.) suspension</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
Placebo: Placebo contains only inert ingredients and is not expected to exert any direct physiological effects</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean LH</title>
          <description>This secondary endpoint is the change of the mean LH (over 10 h), comparing (a) mean LH at baseline to (b) mean LH immediately after progesterone or placebo administration</description>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="2.2"/>
                    <measurement group_id="O2" value="4.6" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean LH Amplitude</title>
        <description>This secondary endpoint is the change in the mean LH amplitude (over 10 h), comparing (a) mean LH amplitude at baseline to (b) mean LH amplitude immediately after progesterone or placebo administration</description>
        <time_frame>10 hours following administration of micronized progesterone or placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Oral Micronized Progesterone Suspension</title>
            <description>oral micronized progesterone (100 mg p.o.) suspension
oral micronized progesterone suspension: oral micronized progesterone (100 mg p.o.) suspension</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
Placebo: Placebo contains only inert ingredients and is not expected to exert any direct physiological effects</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean LH Amplitude</title>
          <description>This secondary endpoint is the change in the mean LH amplitude (over 10 h), comparing (a) mean LH amplitude at baseline to (b) mean LH amplitude immediately after progesterone or placebo administration</description>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.3" spread="2.8"/>
                    <measurement group_id="O2" value="3.6" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From start of study procedures until end of study participation, up to 6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Oral Micronized Progesterone Suspension</title>
          <description>Oral micronized progesterone (100 mg) suspension</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo contains only inert ingredients and is not expected to exert any direct physiological effects</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Irregular Menstrual Bleeding</sub_title>
                <description>Temporary spotting</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Christopher R. McCartney</name_or_title>
      <organization>University of Virginia Center for Research in Reproduction</organization>
      <phone>4342430329</phone>
      <email>cm2hq@virginia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

